Dr. Balaji Prasad, an analyst for investment bank Barclays, called Daxxify the most significant advance in the $3 billion facial-injection field since Botox — which now dominates 70 percent of ...

F.D.A. OKs Daxxify, an Anti-Wrinkle Drug and Botox Competitor The treatment lasts for six months in half of its users, company studies showed, representing the first major advance in facial ...